Notice NOT-OD-23-148 from the NIH Guide for Grants and Contracts

Notice NOT-ES-23-013 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AI-23-039 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to develop new and advance existing diagnostics for congenital and adult acquired syphilis infections by leveraging recent advances in Treponema pallidum basic research and broader infectious disease diagnostic innovations.

Funding Opportunity RFA-CA-23-027 from the NIH Guide for Grants and Contracts. This notice of funding opportunity (NOFO) invites grant applications for a Coordination Center to support four research centers that address the impact of social determinants of health (SDOH) on adverse cancer control outcomes. The Coordination Center will 1) lead efforts to manage and share consortium-wide data; 2) connect research Centers with capacity building and training opportunities and disseminate synthesized research products; 3) stimulate and coordinate consortium collaborative activities, and 4) evaluate the impact of the consortium. One Coordination Center will be funded as part of the Advancing Cancer Control Equity Research through Transformative Solutions (ACCERT) Consortium, to support up to four ACCERT Centers (RFA-CA-23-026).

Funding Opportunity RFA-CA-23-026 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity is to advance cancer control equity research by stimulating community-engaged, multilevel research interventions that address the impact of social determinants of health on adverse cancer outcomes. Applicants will 1) develop interventions that target the multilevel pathways by which social determinants of health impact adverse cancer outcomes; 2) develop methods, measures, and assess community-level SDOH, community engagement, and cancer control equity processes and outcomes; and 3) build capacity among diverse scholars, stakeholders, and community partners to implement interventions that incorporate the lived experiences of those who face cancer inequities.

Funding Opportunity RFA-AT-24-002 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to solicit applications for continuation of a Coordinating Center (CC) to provide national leadership for the NIH-DoD-VA Pain Management Research Collaboratory program on evidence-based non-pharmacological approaches to pain management for U.S. veterans, military personnel, and/or their families. For brevity, this initiative will be referred to as the NIH-DoD-VA Pain Management Collaboratory, or PMC. Coordinating Center applicants will need to: 1) develop, adapt, and adopt technical and policy guidelines and best practices for the effective conduct of research in partnership with health care systems focused on veterans, military personnel, and their families; 2) work collaboratively with and provide technical, design, and other support to Demonstration Project teams, to develop and implement a pragmatic trial protocol; and 3) disseminate widely Collaboratory-endorsed policies and best practices and lessons learned in the Demonstration Projects for implementing research within health care settings. The Coordinating Center will also serve as the central resource for the activities of the NIH-DoD-VA Pain Management Collaboratory program, including providing administrative support for a Steering Committee and its subcommittees.

Funding Opportunity PAR-23-225 from the NIH Guide for Grants and Contracts. The purpose of this NIH Mentored Research Scientist Development Award (K01) is to provide salary and research support to investigators who are within ten years of completing their terminal professional degree or residency training. Research and mentorship must be in the field of HIV/AIDS translational studies, using nonhuman primates (NHPs) as preclinical models. These awards will provide 3 years of support for intensive research career development under the guidance of an experienced mentorship team, with expertise in both the pre-clinical application of NHP HIV/AIDS models and in translation of the results from such studies to clinical application in humans. The expectation is that this sustained experience will launch independent research careers and enable awardees to become competitive for new research project grant (e.g., R01) funding. This funding initiative addresses research priorities of the fiscal year (FY) 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan): reduce the incidence of HIV; develop next-generation HIV therapies; research toward HIV cure; and address HIV-associated comorbidities, coinfections, and complications. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA (FOA #).

Funding Opportunity PAR-23-215 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support preclinical HIV/AIDS research using NHP models performed by Early Stage Investigators (ESIs) who are within 10 years of their terminal degree or completion of their residency training but who have at least two years of postdoctoral experience. The goal of this support is to help advance HIV/AIDS researchers using NHP models in preclinical research by providing a degree of independence for these ESIs to develop new research directions and to position these researchers to be competitive for new research funding (e.g., R01). Proposed projects must use NHPs as preclinical models for HIV/AIDS research This funding initiative encompasses all priorities of the fiscal year (FY) 2021-2025 NIH Strategic Plan for HIV and HIV-Related Research (https://www.oar.nih.gov/hiv-policy-and-research/strategic-plan): reduce the incidence of HIV; develop next-generation HIV therapies; conduct research toward HIV cure; address HIV-associated comorbidities, coinfections, and complications; and advance cross-cutting areas of research.

Notice NOT-AG-23-040 from the NIH Guide for Grants and Contracts

Notice NOT-TR-23-019 from the NIH Guide for Grants and Contracts

Notice NOT-HL-23-098 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-200 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. This NOFO will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase will support research that is in the final states of preclinical development with potential for near-term clinical development. Support for a single phased award that does not need the R61 Exploratory phase is available in the companion R33, PAR-23-205.

Funding Opportunity PAR-23-205 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. Multidisciplinary teams of scientists and clinicians must focus on generating preclinical data that will lead to the development of biological, pharmacological, medical device and/or combination product interventions. The ultimate goal of this program is to make new technological, biological and pharmacological resources available to clinicians and their patients. The steps towards this goal should be clearly delineated in a series of milestones that support the development of a therapeutic or device that will lead to an Investigational New Drug (IND) or Investigational Device Exception (IDE) application to the U.S. Food and Drug Administration (FDA) and/or testing in a clinical trial. The R33 is to focus on advancing a single therapeutic candidate through IND/IDE -enabling studies, filing an IND package with the FDA, and designing future clinical trials. Applicants pursuing early stage applied research should consider the companion (R61/R33) NOFO PA-23-XXX.

Notice NOT-LM-23-003 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-050 from the NIH Guide for Grants and Contracts

Notice NOT-AI-23-051 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-009 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) supports the optimization of promising genome editing-based therapeutic leads for Alzheimer's Disease-Related Dementias (ADRD), towards IND-enabling studies. Specifically, it supports the characterization and optimization of therapeutic lead(s) that show promise as potential genome editing therapeutics, as evidenced by convincing proof-of-concept studies in appropriate models. At the end of the funding period, successful projects will have optimized a genome editing therapeutic candidate with demonstrated bioactivity, manufacturability, biodistribution, in vivo efficacy, and/or target engagement (measurement of proximal downstream effects) and optimal dosing, combined with other properties consistent with the desired clinical application. This NOFO is not specific for any one or group within the ADRD spectrum of disorders. Disorders include; Frontotemporal dementia (FTD), Lewy body dementias (LBD) (including Dementia with Lewy bodies (DLB), Parkinson Disease Dementia (PDD)), Vascular contributions to Cognitive Impairment and Dementia (VCID), and Multiples Etiology Dementias (MED).

Funding Opportunity RFA-NS-24-025 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is toinvite applications that aggregate and analyze existing data in the COVID-19 Neuro Databank-Biobank (NeuroCOVIDProject).TheNeuroCOVIDProject was establishedin 2020 to serve as a robust national resource to understand theneurological complicationsassociated with COVID-19 and the effects of COVID-19 on pre-existing neurological conditions. The NeuroCOVID Project has collected and curated a wide range of data from the United States and international sites. This NOFO encourages hypothesis-driven applications to further scientific knowledge of neurological complications ofCOVID-19 by using this de-identified database. Thedata may be combined with data from other U.S. and International databases for analyses.However,collection of new primary data from those affected by COVID-19 or comparison cohorts isNOT covered by this NOFO.

Notice NOT-DE-23-008 from the NIH Guide for Grants and Contracts

Notice NOT-HS-23-017 from the NIH Guide for Grants and Contracts